면역관문억제제(ICI)로 치료받은 흑색종 환자에서 초기 FDG PET/CT와 ctDNA의 상관관계
면역관문억제제로 치료받은 진행성 흑색종 환자의 초기 간격 18F-플루오로데옥시글루코스 양전자 방출 단층촬영/컴퓨터 단층촬영(PET/CT)과 순환 종양 DNA(ctDNA) 사이의 상관관계
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This is a pilot, prospective, observational study to estimate the degree to which baseline and early interval 18F-FDG PET/CT imaging within 3-4 weeks of ICI therapy initiation can accurately correlate with ctDNA level trends, predict clinical response, onset of immune-related adverse events, and survival outcomes in advanced stage melanoma patients.
Primary Objective
• To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks correlates with ctDNA level changes in advanced melanoma patients.
Secondary Objectives
- To determine if early interval response assessment with 18F-FDG PET/CT during initial treatment with ICI therapy at 3-4 weeks predicts clinical efficacy at standard disease assessment time points in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT predicts development of clinical irAEs in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts progression-free survival (PFS) in advanced melanoma patients.
- To assess if early interval response assessment with 18F-FDG PET/CT and ctDNA level predicts overall survival (OS) in advanced melanoma patients.
연구 유형
연구 유형
등록 (실제)
등록
연락처 및 위치
연구 장소
-
-
Wisconsin
-
Madison, Wisconsin, 미국, 53792
- University of Wisconsin Hospitals and Clinics (UWHC)
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
24 participants with advanced stage III or stage IV melanoma with measurable disease who are deemed appropriate for treatment with ICI therapy.
설명
Inclusion Criteria:
- Willing to provide informed consent.
- Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned.
- Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy.
- Individuals at least 18 years of age.
- Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study.
- Willing to comply with all study procedures and be available for the duration of the study.
Exclusion Criteria:
- Not able to receive treatment with ICI therapy
- Use of investigational drugs, biologics, or devices within 30 days prior to enrollment.
- Women who are pregnant, lactating, or planning on becoming pregnant during the study.
- Not suitable for study participation due to other reasons at the discretion of the investigators.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
개입 / 치료개입 / 치료 |
|---|---|
|
면역관문억제제를 사용하는 진행성 흑색종 환자
|
research scan 3-4 weeks after start of immunotherapy
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in ctDNA level from baseline to 3-4 week after the start of therapy
기간: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
ctDNA level is monitored per standard of care in this population, data from chart review. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Change in 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
기간: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy reported as SUV max. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Correlation between ctDNA level change and 18F-FDG PET/CT response from baseline to 3-4 week after the start of therapy
기간: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT response assessment at baseline and at 3-4 weeks after starting ICI therapy with quantitative changes in ctDNA levels at baseline and at 3-4 weeks after starting ICI therapy. Pearson's or Rank's correlation coefficient will be used to measure the baseline measures for ctDNA level trends and PET/CT responses and for those measurements at 3-4 weeks. |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
|
Diagnostic Accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition as measured by Area under the Curve
기간: baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
Receiver-operator curve analysis will be performed to determine the diagnostic accuracy of ctDNA level trend and PET/CT imaging for predicting growth inhibition (area under the curve). |
baseline to 3-4 weeks after start of therapy (up to 5 weeks on study)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. ORR is Partial Response (PR) plus Complete Response (CR). |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Disease Control Rate (DCR)
기간: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate lesion-level and patient-level 18F-FDG PET/CT treatment response assessment at baseline and at 3-4 weeks after starting ICI therapy with clinical response evaluations (RECIST, PERCIST, PECRIT, iRECIST, irRECIST) at 3, 6, 9, and 12 months after the first ICI dose. DCR is Stable Disease (SD) plus PR plus CR. |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Change in Standard Uptake Value (SUV) metrics with onset of Immune Related Adverse Events (irAE)
기간: up to 12 months after the first ICI dose (approximately 1 year on study)
|
Correlate organ-level FDG uptake and changes from the baseline and early 18F-FDG PET/CT assessment with onset of first, second, and third symptomatic irAE per CTCAE v5.0 |
up to 12 months after the first ICI dose (approximately 1 year on study)
|
|
Progression Free Survival (PFS)
기간: up to 3 years after the first ICI dose (approximately 3 years on study)
|
PFS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and PFS
기간: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT treatment response with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and PFS
기간: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Progression Free Survival (PFS) as measured from the date of initiation of ICI treatment until the criteria for disease progression is met as defined by RECIST, PECRIT, or death occurs. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Overall Survival (OS)
기간: up to 3 years after the first ICI dose (approximately 3 years on study)
|
OS will be summarized using Kaplan-Meier estimates of the median survival times. Point estimates as well as 95% confidence intervals will be provided |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for 18F-FDG PET/CT response at 3-4 weeks after the start of therapy and OS
기간: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early 18F-FDG PET/CT response assessment with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
|
Correlation Coefficient for ctDNA level at 3-4 weeks after the start of therapy and OS
기간: up to 3 years after the first ICI dose (approximately 3 years on study)
|
Correlate early ctDNA level trends with Overall Survival (OS) as measured from the date of initiation of ICI treatment until date of death from any cause. |
up to 3 years after the first ICI dose (approximately 3 years on study)
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Vincent Ma, MD, University of Wisconsin, Madison
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 2023-1089
- A534260 (기타 식별자: UW Madison)
- UW23077 (기타 식별자: UWCCC)
- Protocol Version 2/12/2024 (기타 식별자: UW Madison)
- NCI-2023-11059 (레지스트리 식별자: NCI Trial ID)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .